Soleno Therapeutics (NASDAQ: SLNO) surged more than 33% in premarket trading on Monday, April 6, 2026, after Neurocrine Biosciences (NASDAQ: NBIX) announced a definitive agreement to acquire the company for $53.00 per share in an all-cash deal valued at approximately $2.9 billion